Clinical trials: Soft Tissue Sarcoma (STS)
Bone Sarcoma, Soft Tissue Sarcoma (STS)
"Exercise Intervention to Increase Physical Activity in Young Sarcoma Survivors (Sport Ist Herzenssache)"
Survivors of bone and soft tissue sarcoma often face long-term health problems after their cancer treatment, such as muscle weakness, joint stiffness, and reduced heart and lung fitness.
- Trial name
- NCT07729059
- Testing
- Individualized Exercise Program
- Volunteers
- 46 people
- Sponsor
- Universität Duisburg-Essen
Solid Tumor, Colon Carcinoma
PET-imaging of Two Vartumabs in Patients With Solid Tumors
VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS).
- Conditions
- Solid Tumor, Colon Carcinoma, Rectal Carcinoma, Osteosarcoma
- Trial name
- VARTUTRACE (NCT06645808)
- Testing
- 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Var2 Pharmaceuticals
Soft Tissue Sarcoma
Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
This is a phase 1b study of investigational drug selinexor in combination with doxorubicin in patients with locally advanced or metastatic soft tissue sarcoma.
- Trial name
- NCT03042819
- Testing
- Selinexor, Doxorubicin
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- University Health Network, Toronto
Metastatic Adult Soft Tissue Sarcoma
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.
The main objective of the trial is to document the preliminary antitumor activity of two doses of NGR-hTNF administered either alone or in combination with doxorubicin in locally advanced or metastatic soft-tissue sarcoma (STS)…
- Trial name
- NCT00484341
- Testing
- low-dose NGR-hTNF, high-dose NGR-hTNF, Doxorubicin
- Where
- 7 sites in France, Italy and 1 more
- Volunteers
- 69 people
- Sponsor
- AGC Biologics S.p.A.
Advanced Soft Tissue Sarcoma
A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in aSTS in a Real World Setting in Greece
This non-interventional study aims primarily at assessing the clinical effectiveness and the impact of the therapy on cancer-related symptoms and patients' HRQoL.
- Trial name
- beYOND-STS (NCT02618122)
- Where
- Greece
- Volunteers
- 63 people
- Sponsor
- Genesis Pharma S.A.
Sarcoma, Soft Tissue
Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)
The aims of this trial are to evaluate the efficacy of bendamustin in patients with metastatic soft tissue sarcoma who have progressed after or during an anthracycline-baesd chemotherapy and to assess the treatment of toxicity.
- Trial name
- NCT00204620
- Testing
- Bendamustin
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- University Hospital Tuebingen
Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer
EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
MDG1015 is a third generation TCR-T therapy product targeting NY-ESO-1/LAGE-1a armored and enhanced by the PD1-41BB costimulatory switch protein (CSP).
- Conditions
- Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma
- Trial name
- EPITOME-1015-I (NCT06748872)
- Testing
- Lymphodepletion, TCR-T cells (MDG1015)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Medigene AG
Soft Tissue Sarcoma (STS)
A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.
This study intends to enroll patients with advanced soft tissue sarcoma, employing immunotherapy combined with eribulin, anlotinib, and radiotherapy as subsequent-line treatment to preliminarily explore its efficacy and safety.
- Trial name
- NCT07205185
- Testing
- QL1706 + Eribulin + Anlotinib + Radiotherapy
- Volunteers
- 46 people
- Sponsor
- Fudan University
Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
The primary objectives of the study are: Determine the safety and maximum tolerated dose (MTD) of IPI-504 in GIST and STS patients who have failed prior therapies Recommend a dose for subsequent studies of IPI-504
- Trial name
- NCT00276302
- Testing
- IPI-504
- Where
- 5 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Sarcoma
Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00064220
- Testing
- soblidotin
- Where
- 6 sites in United States, Puerto Rico
- Sponsor
- Daiichi Sankyo
Soft Tissue Sarcoma (STS), Bronchoalveolar Lavage (BAL)
BAL Fluid Biomarkers in Sarcoma
This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients.
- Conditions
- Soft Tissue Sarcoma (STS), Bronchoalveolar Lavage (BAL), Bronchoalveolar Lavage Fluid
- Trial name
- NCT06815666
- Testing
- Bronchoscopy & Metastasectomy
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- University Health Network, Toronto
Soft Tissue Sarcoma (STS)
5-AminoLevulinic Acid Aided Resection Margins in Sarcoma
The goal of this study is to learn if the intervention using a fluorescent agent 5-Aminolevulinic acid (5-ALA) to aid in the surgical approach to visualize the soft-tissue sarcoma (STS) during surgical resection.
- Trial name
- 5-ALARMS (NCT07038278)
- Testing
- 5-ALA
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
Soft Tissue Sarcoma (STS), Utidelone
Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma
This trial is an open, multicenter, phase II clinical trial evaluating the efficacy and safety of uterostatin capsules (UTD2) combined with doxorubicin and tislelizumab in the treatment of advanced soft tissue sarcoma.
- Conditions
- Soft Tissue Sarcoma (STS), Utidelone, Doxorubicin
- Trial name
- NCT07842276
- Testing
- UTD2 + tislelizumab + doxorubicin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Cancer
Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab
Soft tissue sarcomas represent a subtype of cancer that is both rare and very heterogeneous. When they are organized, their current treatment is essentially based on tumor resection surgery, +/- associated with treatment by…
- Trial name
- NeoSarc (NCT06116578)
- Testing
- Pembrolizumab, Pembrolizumab and Olaparib, Pembrolizumab adjuvant
- Where
- France
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Sarcoma
Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS
The proposed investigation intends to explore if the combination of trabectedin and doxorubicin in the first line of treatment of advanced sarcomas obtains better results than doxorubicin monotherapy
- Trial name
- NCT01104298
- Testing
- Doxorubicin, Trabectedin
- Where
- 20 sites in Spain
- Volunteers
- 115 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
Sarcoma, Soft Tissue
Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS)
Complete resection is still the only curative treatment option in patients with soft tissue sarcoma (STS). Patients with a non-resectable STS have a dismal prognosis even without evidence of metastatic disease.
- Trial name
- NCT00204646
- Testing
- Adriamycin, Ifosfamide, Etoposide
- Where
- Germany
- Sponsor
- University Hospital Tuebingen
Soft Tissue Sarcoma, Xenograft Model
A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS)
Outside the setting of well-designed prospective clinical studies, the current standard preoperative RT should be a conventionally 1.8-2 Gy fractionated regimen to a total dose of 50 Gy in 5-6 weeks.
- Conditions
- Soft Tissue Sarcoma, Xenograft Model, 2D/3D Cell Cultures
- Trial name
- SarcomaPDX (NCT02910895)
- Testing
- tumor biopsy
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- The Netherlands Cancer Institute
Sarcoma, Bone Sarcoma
Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention
This study will evaluate strategies to improve physical function and promote exercise and physical activity in adolescents and young adults (AYAs) with sarcoma.
- Conditions
- Sarcoma, Bone Sarcoma, Soft Tissue Sarcoma (STS)
- Trial name
- AYA-ONE (NCT07662239)
- Testing
- Exercise Triage and Personalized Exercise Program
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Resectable Soft Tissue Sarcoma, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Shorter Course, Hypofractionated Pre-Surgery Radiation Therapy in Treating Patients With Localized, Resectable Soft Tissue Sarcoma of the Extremity of Superficial Trunk
This phase II trial studies the wound complication risk of shorter course, hypofractionated pre-surgery radiation therapy in treating patients with localized soft tissue sarcoma of the extremity of superficial trunk that can be…
- Conditions
- Resectable Soft Tissue Sarcoma, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Trial name
- NCT03819985
- Testing
- Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- M.D. Anderson Cancer Center
Soft Tissue Sarcoma (STS)
A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.
This trial will Study a type of sarcoma defined metastatic soft-tissue sarcoma (STS). Participants will be treated with bexmarilimab, a CLEVER-1 antibody plus doxorubicin, a chemotherapy.
- Trial name
- BEXAR (NCT07460986)
- Testing
- bexmarilimab, Doxorubicin
- Where
- 11 sites in Spain
- Volunteers
- 278 people
- Sponsor
- MedSIR